| Volume: | 17,143,288 |
|---|---|
| Day's Low: | $36.32 |
| 52-wk Low: | $31.25 |
| Previous Close: | $36.59 |
| Dividend: | $0.38 |
| Market Cap: | 113,394,900 |
| Avg Volume: | 15,090,500 |
|---|---|
| Day's High: | $37.17 |
| 52-wk High: | $41.56 |
| Open Price: | $36.93 |
| Yield: | 4.15% |
| P/E (Forward): | 10.58 |
| 11:35 AM | 2/9/2010 | UPDATE: Biogen 4Q Profit Up 48%; Offers Bright 2010 Forecast |
| 9:20 AM | 2/9/2010 | Biogen: Heart Drug Data Doesn't Support Continued Development |
| 4:09 PM | 2/5/2010 | Sanofi Nears Decision On Combining Animal Unit With Merck's |
| 12:44 PM | 2/4/2010 | Merck Delays Return Of ProQuad Childhood Vaccine |
| 4:20 PM | 2/3/2010 | MARKET SNAPSHOT: U.S. Stocks Snap Win-streak As Health Shares Drop |
| 3:45 PM | 2/3/2010 | MARKET SNAPSHOT: U.S. Stocks Head For Lower Close |
| 2:46 PM | 2/3/2010 | MARKET SNAPSHOT: U.S. Stocks Falter As Earnings Reports Fall Short |
| 2/9/2010 | Pfizer Off 2% As 2010 Targets Miss; Posts Revised 2012 Targets (Barrons.com) |
| 2/9/2010 | McGinn Likes Ford, Citi, Merck, Pfizer (Barrons.com) |
| 2/9/2010 | Investors Seek More Disclosure on Political Spending (WSJ.com) |
| 2/9/2010 | Republicans and Democrats will debate on TV, but little may come of it. (The Motley Fool) |
| 2/9/2010 | Or at least take a moment to read this first! (The Motley Fool) |
| 2/9/2010 | Amgen's Prolia passes another test on its way to potential blockbuster status. (The Motley Fool) |
| 2/9/2010 | Dividends are great, but dividends that the rest of the market overlooks can be even better. (The Motley Fool) |
| 2/9/2010 | Tysabri Boosts Biogen Earnings (WSJ.com) |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.90 | 0.80 | 12.50 |
| EPS, GAAP | 0.29 | 0.51 | -43.14 |
| Consensus Estimate | 0.82 | 0.79 | 3.80 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 3.34 | 3.42 | -2.34 |
| EPS, GAAP | 1.91 | 2.10 | -9.05 |
| Consensus Estimate | 3.11 | NA | NA |
| MRK | Industry Average | |
| P/E (TTM) | 19.16 | 14.70 |
| P/E (Forward) | 10.58 | 12.60 |
| PEG Ratio | 2.41 | 1.45 |
| Price/Sales | 3.08 | 2.51 |
| Beta | 0.88 | 0.88 |